Pressure BioSciences, Inc. (PBIO)
Market Cap | 15.28M |
Revenue (ttm) | 1.44M |
Net Income (ttm) | -15.50M |
Shares Out | 12.22M |
EPS (ttm) | -2.09 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 8,512 |
Open | 1.42 |
Previous Close | 1.39 |
Day's Range | 1.38 - 1.42 |
52-Week Range | 0.91 - 2.40 |
Beta | 0.78 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About PBIO
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also di... [Read more]
Financial Performance
In 2021, PBIO's revenue was $2.00 million, an increase of 64.05% compared to the previous year's $1.22 million. Losses were -$20.15 million, 25.9% more than in 2020.
Financial StatementsNews

Pressure BioSciences Receives $1.5M Contract for UltraShear Nanoemulsified CBD
CBD Supply MD, a Leading Maryland-Based CBD Retailer, to Introduce PBIO's UltraShear Processed, Best-in-Class Nanoemulsified CBD Products Across the Multi-State Mid-Atlantic Region SOUTH EASTON, MA / ...

Pressure BioSciences Announces the Exchange of Over $10 Million of Debt into Equity
Company's Largest Investor Exchanges First Seniority Debt into Non-Secured Equity at 38% Above-Market Price, Expressing Confidence and Support SOUTH EASTON, MA / ACCESSWIRE / March 1, 2023 / Pressure ...

Pressure BioSciences Receives Record Nearly $600,000 Order for 16 PCT Instruments
Largest Single Order in Company's History was Prepaid as New Chinese Distributor Comes Online; Adds to Revenue Strength Also Building Across PBI's UltraShear Nanoemulsions Platform SOUTH EASTON, MA / ...

Pressure BioSciences and One World Products Announce Partnership in Development of CBD-Nanoemulsion Sports Performance/Recovery Drinks
NBA Legend Isiah Thomas Leads Effort to Innovate and Deliver Next Generation Sports Drinks SOUTH EASTON, MA / ACCESSWIRE / January 27, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Com...

Pressure BioSciences Nanoemulsions Platform Forging Game-Changing Future for Cannabis Industry
Dramatic Consumer Testing Results Confirm UltraShear Nanoemulsion THC Oral Spray Delivers First Effects and Maximization in Lightning Speed - Simple, Reliable Dosing Delivers Profoundly Improved Resul...

Pressure BioSciences Gives Guidance for Strong Q4 2022 Sales Followed by Rapid Revenue Growth from Multiple Large Industries in 2023
Foundations Built and Momentum Achieved in 2022 Expected to Drive Company to Significant Revenue Levels, Up-list, and Profitability in 2023: The Stage Has Been Set SOUTH EASTON, MA / ACCESSWIRE / Dece...

Pressure BioSciences Announces First Commercial Production of Revolutionary UltraShear Nanoemulsion Product Shipped, Booked, and Paid
$75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up Scheduled for Early 2023 - Expected to Yield 1st Half 2023 Revenues Over $1 Mill...

Pressure BioSciences Partnership with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiveness in Skin Tightening and Wrinkle Reduction
Renowned Skincare Expert Dr. Adrienne Denese Confirms PBI's UltraShear Nanoemulsion of Retinoate Profoundly Exceeds All Performance Expectations in Development of Next Generation Skincare Products SOU...

Pressure BioSciences Securing and Fulfilling UltraShear Nanoemulsions Contracts, Discussed on "Stock Day Podcast"
Phoenix, Arizona--(Newsfile Corp. - December 5, 2022) - The Stock Day Podcast recently welcomed Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or "the Company"), a leader in the development and sale ...

Pressure BioSciences, Inc. Reports Q3 2022 Financial Results and Offers Business Update on Ultra Shear Technology Nanoemulsions Commercialization Progress
Resources Continue to Pivot to UST Platform Commercialization, Achieving Major Progress and Traction; Revolutionary Nanoemulsions Technology Expected to Drive Major Growth to Profitability in 2023 Inv...

Pressure BioSciences, Inc. to Discuss Third Quarter 2022 Financial Results and Provide Business Update
Conference Call Scheduled for Tuesday November 22 at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / November 21, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced tha...

7 Stocks to Sell Right Now
Once again, I drew the short (no pun intended) end of the stick and must discuss stocks to sell right now. Understandably a sensitive topic and one that arouses myriad emotions, I'm just going to stic...

Pressure BioSciences and Leading Cosmeceuticals Innovator Dr. Denese SkinScience to Introduce Revolutionary UST Nanoemulsion Hair Regrowth Product in 2023
Dormant Hair Follicles to be More Effectively Revitalized by Nutrients and Therapeutics Delivered Quickly and Potently via Extremely Fine Droplet Sizes Produced from Patented UST Nanoemulsion Technolo...

Pressure BioSciences and Leading Cosmeceuticals Company Dr. Denese SkinScience Present Their Partnership Progress in FORCE Family Office October 13th Webinar
Companies Will Discuss Actions and Planning Completed for a New Generation of Skincare Products, Offering Revolutionary Effectiveness Through Combination of PBI's UST Best-in-Class Nanoemulsification ...

Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at H. C. Wainwright Annual Global Investment Conference on September 13th
Company Shifts Primary Business Focus to Revolutionary UST Platform. Expects to Enter FY 2023 with Ten or More Tolling Contracts.

Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform With Dr. Denese SkinScience, 20-Year Leader With Over $0.5 Billion in QVC Sales
Collaborative UST-Driven Research and Development Agreement Announced With Dr. Adrienne Denese (QVC Icon, Skincare Visionary, Anti-Aging Pioneer, & Creator of Award-Winning SkinScience Labs) Targets R...

Pressure BioSciences Announces Contract for October 2022 Launch of Breakthrough Hemp-Derived CBD Product, Estimating $2 Million Incremental 2023 Revenue
Canopy CBD Farms, with Multiple Sales Channels and Industry Contacts Nationwide, Partners with PBI to Commercialize Revolutionary Hemp-Derived CBD Product, Offering Unparalleled Topical Effectiveness ...

Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update
Conference Call Scheduled for Thursday August 18 at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / August 16, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that t...

Pressure BioSciences Announces Approval to Manufacture Hemp-Derived CBD Products in Massachusetts, Including Their Revolutionary CBD Nanoemulsions
Canopy CBD Farms, MA-licensed North American Processor/Manufacturer/Distributor of CBD Products Derived from Hemp, Received State Approval Covering PBI's Manufacture of CBD Nanoemulsions for Sale to M...

Pressure BioSciences Doubles Growth Projections for UST Nanoemulsion Contracts Following Clear Confirmation of Unmet Needs in Exploding Cannabis Drinks Sector
Conferences on West Coast and Midwest Illuminate Rapid Market Expansion of Cannabis Beverages and Critical Role for UST Nanoemulsions to Revolutionize Effective Precision Dosing and Delivery SOUTH EAS...

Pressure BioSciences Announces Second Contract for Toll Manufacturing of a CBD Nanoemulsion Product Using Its Proprietary Ultra Shear Technology Platform
PBI Partners with Leading Colorado Cannabis Company for Manufacture and Distribution of Novel Nano-CBD Topical Spray and Other Products, Anticipating $2 Million in 2023 Revenue Contribution SOUTH EAST...

Pressure BioSciences to Expand on Upcoming Release of CBD Nanoemulsion Oral Spray at July 6th Emerging Growth Conference - Annual Revenue to PBI Expected to Exceed $1M
Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive Update/Q&A Session SOUTH EASTON, MA / ACCESSWIRE / July 6, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" ...

Pressure BioSciences to Participate in FORCE Family Office June 30th Webinar: Revolutionizing the Development of Plant-Based Food Products
Investors, Analysts, and Advisors Invited to Attend this Real-Time, Interactive Presentation/Q&A Event SOUTH EASTON, MA / ACCESSWIRE / June 30, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" an...

Pressure BioSciences Announces Contracted Production Launch for Estimated $3,000,000 of UST-Processed, Nanoemulsified CBD Spray for Oral Use
Safer Medical of Montana, a Seasoned Distributor of Wellness Products with a Focus on Veterans, Partners with PBI as Exclusive Distributor for Highly Stable and Water-Soluble CBD Oral Aerosol Product ...

Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market
Recent Study Published by The Ohio State University Illuminates Unique Capabilities of PBI's UST Platform for Optimal Formulation and Processing of New and Existing Plant Protein-based Beverages SOUTH...